https://mml.aeb.mwp.accessdomain.com/2017/03/02/complaint-genentech-v-amgen-dismissed-without-prejudice-2/ 2017-03-02T18:38:42+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2017/03/02/complaint-genentech-v-amgen-dismissed-without-prejudice/ 2017-03-06T03:56:24+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2017/02/16/fda-accepts-bla-mylan-biocon-pegfilgrastim-biosimilar/ 2017-03-06T05:34:53+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/01/Rx-pharmacy.jpg https://mml.aeb.mwp.accessdomain.com/2017/02/08/fda-provides-snapshot-biosimilars-development-programs/ 2017-03-06T18:56:07+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Flask-Perodic-Table-Structures.jpg https://mml.aeb.mwp.accessdomain.com/2017/02/27/celltrions-truxima-rituximab-approved-europe/ 2017-03-06T21:04:19+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/World-Map.jpg https://mml.aeb.mwp.accessdomain.com/2017/02/20/genentech-sues-amgen-bpcia-disclosures-avastin-bevacizumab/ 2017-03-09T17:38:20+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Scales-of-Justice.jpg https://mml.aeb.mwp.accessdomain.com/2017/03/22/sanofi-regeneron-seek-declaratory-judgment-dupixent-dupilumab-not-infringe-amgens-patent/ 2017-03-22T21:17:19+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2017/01/15/nonproprietary-naming-biological-products/ 2017-03-25T04:38:36+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/01/Rx-pharmacy.jpg https://mml.aeb.mwp.accessdomain.com/2017/03/27/amgens-amgevita-receives-approval-europe/ 2017-03-27T14:16:37+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/World-Map.jpg https://mml.aeb.mwp.accessdomain.com/2017/01/21/hospira-files-three-ipr-petitions-herceptin-patents/ 2017-04-03T18:20:57+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Patent-Illustration.jpg https://mml.aeb.mwp.accessdomain.com/2017/01/31/hospira-files-two-ipr-petitions-herceptin-patents/ 2017-04-03T18:21:34+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Network-connection.jpg https://mml.aeb.mwp.accessdomain.com/2017/02/22/celltrion-files-ipr-petition-herceptin-patent/ 2017-04-03T18:22:46+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Patent-Illustration.jpg https://mml.aeb.mwp.accessdomain.com/2017/02/28/ptab-institutes-ipr-filed-celltrion-rituximab-patent/ 2017-04-03T18:23:25+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Gavel.jpg https://mml.aeb.mwp.accessdomain.com/2017/03/01/rfems-biosimilar-inter-partes-review-ipr-dashboard/ 2017-04-03T18:23:53+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/United-States-Seal.jpg https://mml.aeb.mwp.accessdomain.com/2017/03/07/ptab-denies-celltrions-request-ipr-838-patent/ 2017-04-03T18:24:28+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/glass-vials.jpg https://mml.aeb.mwp.accessdomain.com/2017/03/09/samsung-bioepsis-biogen-fujifilm-invalidate-humira-patents-uk/ 2017-04-03T18:29:58+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/World-Map.jpg https://mml.aeb.mwp.accessdomain.com/2017/03/16/rfems-biosimilar-inter-partes-review-ipr-dashboard-2/ 2017-04-03T18:30:57+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2016/08/RF-Generic-Logo-sm.jpg https://mml.aeb.mwp.accessdomain.com/2017/03/17/celltrion-files-three-ipr-petitions-rituximab-patents/ 2017-04-03T18:31:52+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Patent-Illustration.jpg https://mml.aeb.mwp.accessdomain.com/2017/04/03/pfizer-files-ipr-petition-rituximab-patent/ 2017-04-03T18:33:35+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/glass-vials.jpg https://mml.aeb.mwp.accessdomain.com/2017/04/04/celltrion-files-three-ipr-petitions-two-rituximab-patents/ 2017-04-04T20:19:35+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Flask-Perodic-Table-Structures.jpg https://mml.aeb.mwp.accessdomain.com/2017/03/30/sanofi-regeneron-follow-declaratory-judgment-complaint-ipr-petition-fda-approves-dupixent-dupilumab/ 2017-04-12T15:42:24+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/United-States-Seal.jpg https://mml.aeb.mwp.accessdomain.com/2017/04/12/immunex-files-patent-infringement-suit-dupixent-dupilumab-seeks-dismiss-transfer-sanofi-regenerons-prior-dj-complaint/ 2017-04-12T19:59:33+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Scales-of-Justice.jpg https://mml.aeb.mwp.accessdomain.com/2017/01/20/fda-issues-draft-guidance-demonstrating-interchangeability/ 2017-04-14T21:11:06+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/glass-vials.jpg https://mml.aeb.mwp.accessdomain.com/2017/04/20/patent-dance-goes-genentech-amgen-bevacizumab-avastin/ 2017-04-20T19:54:15+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/04/patent-dance.jpg https://mml.aeb.mwp.accessdomain.com/2017/04/24/fda-approves-fifth-biosimilar-samsung-bioepiss-renfexis-infliximab-abda/ 2017-04-24T18:49:03+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Network-connection.jpg https://mml.aeb.mwp.accessdomain.com/2017/05/03/pfizer-files-ipr-petitions-three-rituximab-patents/ 2017-05-03T17:46:45+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Patent-Illustration.jpg https://mml.aeb.mwp.accessdomain.com/2017/04/19/litigation-spotlight-infliximab-remicade-litigation/ 2017-05-04T23:36:23+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/04/RF_ROT_172628414_low.jpg https://mml.aeb.mwp.accessdomain.com/2017/05/08/sanofi-genzyme-regeneron-voluntarily-dismiss-dupixent-dupilumab-declaratory-judgment-suit-massachusetts/ 2017-05-08T14:58:06+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Gavel.jpg https://mml.aeb.mwp.accessdomain.com/2017/05/12/baxalta-files-patent-infringement-suit-genentech-chugai-antibody-hemophilia-emicizumab/ 2017-05-12T18:10:39+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Antibody.jpg https://mml.aeb.mwp.accessdomain.com/2017/05/10/litigation-spotlight-apotex-filgrastim-neupogen-pegfilgrastim-neulasta-litigation/ 2017-05-12T19:28:14+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/04/RF_ROT_172628414_low.jpg https://mml.aeb.mwp.accessdomain.com/2017/04/28/supreme-court-hears-oral-argument-first-biosimilar-case/ 2017-05-17T16:04:45+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2017/04/14/briefing-completed-supreme-courts-first-biosimilar-case/ 2017-05-17T16:05:43+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2017/01/26/supreme-court-decides-hear-biosimilar-case/ 2017-05-17T16:06:44+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2017/05/26/partner-nikki-gifford-presents-world-biosimilar-congress-usa-2017/ 2017-05-26T14:45:24+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2016/08/RF-Generic-Logo-sm.jpg https://mml.aeb.mwp.accessdomain.com/2017/05/30/janssen-files-bpcia-patent-infringement-suit-samsung-bioepiss-renflexis-infliximab-abda/ 2017-05-30T16:30:27+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Scales-of-Justice.jpg https://mml.aeb.mwp.accessdomain.com/2017/05/31/fda-advisory-committee-recommends-approval-pfizers-proposed-biosimilar-amgens-epogenprocrit-epoetin-alfa/ 2017-05-31T16:34:40+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/glass-vials.jpg https://mml.aeb.mwp.accessdomain.com/2017/05/02/celltrion-submits-application-herzuma-traztuzumab-japan-launches-truxima-rituximab-europe/ 2017-06-02T21:07:57+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/World-Map.jpg https://mml.aeb.mwp.accessdomain.com/2017/05/18/celltrion-challenges-another-herceptin-patent-two-new-ipr-petitions/ 2017-06-02T21:10:05+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/United-States-Seal.jpg https://mml.aeb.mwp.accessdomain.com/2017/03/24/celltrion-targets-four-herceptin-patents-ipr-petitions/ 2017-06-02T21:11:52+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Network-connection.jpg https://mml.aeb.mwp.accessdomain.com/2017/03/20/ptab-institutes-first-ipr-bevacizumab-patent/ 2017-06-02T21:12:52+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Scales-of-Justice.jpg https://mml.aeb.mwp.accessdomain.com/2017/03/16/ptab-institutes-hospiras-ipr-herceptin-patent/ 2017-06-02T21:14:08+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/United-States-Seal.jpg https://mml.aeb.mwp.accessdomain.com/2017/03/10/genentech-mylan-settle-iprs-carter-213-antibody-patent/ 2017-06-02T21:15:40+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Antibody.jpg https://mml.aeb.mwp.accessdomain.com/2017/06/02/pfizer-challenges-genentechs-carter-213-antibody-patent-two-new-ipr-petitions/ 2017-06-03T13:47:06+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Antibody.jpg https://mml.aeb.mwp.accessdomain.com/2017/06/05/litigation-spotlight-epoetin-alfa-epogen-litigation/ 2017-06-05T20:15:16+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/04/RF_ROT_172628414_low.jpg https://mml.aeb.mwp.accessdomain.com/2017/06/08/fda-advisory-committee-meeting-announced-amgens-allergans-proposed-biosimilar-avastin-bevacizumab/ 2017-06-08T18:56:03+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Flask-Perodic-Table-Structures.jpg https://mml.aeb.mwp.accessdomain.com/2017/06/08/fujifilm-kyowa-kirin-biologics-announces-application-humira-adalimumab-biosimilar-accepted-ema/ 2017-06-08T19:25:49+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/World-Map.jpg https://mml.aeb.mwp.accessdomain.com/2017/06/12/litigation-spotlight-update-saga-continues-infliximab-remicade-litigation/ 2017-06-12T20:13:07+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/04/RF_ROT_172628414_low.jpg https://mml.aeb.mwp.accessdomain.com/2017/06/27/overview-important-changes-bsufa-ii/ 2017-06-27T19:10:25+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/01/Rx-pharmacy.jpg https://mml.aeb.mwp.accessdomain.com/2017/02/01/coherus-files-four-ipr-petitions-humira-patent/ 2017-06-27T22:01:32+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2016/08/RF-Generic-Logo-sm.jpg https://mml.aeb.mwp.accessdomain.com/2017/06/26/samsung-bioepiss-imraldi-adalimumab-recommended-approval-europe/ 2017-06-28T15:34:03+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Network-connection.jpg https://mml.aeb.mwp.accessdomain.com/2017/06/28/fda-unexpectedly-rejects-pfizers-application-epoetin-alfa-biosimilar/ 2017-06-28T18:45:40+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/glass-vials.jpg https://mml.aeb.mwp.accessdomain.com/2017/06/29/sandozs-rixathon-rituximab-approved-europe/ 2017-06-29T14:51:21+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Antibody.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/06/Sandoz%E2%80%99s-Rixathon%C2%AE-rituximab-Approved-in-Europe.png https://mml.aeb.mwp.accessdomain.com/2017/07/03/celltrions-application-rituxan-rituximab-biosimilar-accepted-fda/ 2017-07-03T14:41:40+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Flask-Perodic-Table-Structures.jpg https://mml.aeb.mwp.accessdomain.com/2017/07/06/will-tc-heartland-impact-bpcia-hatch-waxman-litigation/ 2017-07-06T20:38:33+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2017/07/06/will-tc-heartland-impact-bpcia-hatch-waxman-litigation-2/ 2017-07-06T20:38:33+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2017/07/11/pfizer-challenges-another-herceptin-patent-two-new-ipr-petitions/ 2017-07-11T20:56:35+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/United-States-Seal.jpg https://mml.aeb.mwp.accessdomain.com/2017/07/14/update-bsufa-ii-clears-house-awaits-senate-vote/ 2017-07-14T17:45:39+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/01/Rx-pharmacy.jpg https://mml.aeb.mwp.accessdomain.com/2017/07/17/boehringer-ingelheim-prevails-ipr-abbvies-135-humira-patent/ 2017-07-17T15:34:31+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/United-States-Seal.jpg https://mml.aeb.mwp.accessdomain.com/2017/07/18/fda-advisory-committee-recommends-approval-car-t-cell-therapy-two-new-biosimilars/ 2017-07-18T18:10:02+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Flask-Perodic-Table-Structures.jpg https://mml.aeb.mwp.accessdomain.com/2017/07/21/supreme-courts-decision-amgen-v-sandoz-clear-guidance-open-questions-biosimilars/ 2017-07-21T18:07:38+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Gavel.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/07/Patent-Dance-Steps.png https://mml.aeb.mwp.accessdomain.com/2017/07/25/fda-grants-tentative-approval-mercks-insulin-glargine/ 2017-08-01T23:27:52+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Flask-Perodic-Table-Structures.jpg https://mml.aeb.mwp.accessdomain.com/2017/08/02/litigation-spotlight-update-epoetin-alfa-epogen-litigation/ 2017-08-02T14:02:13+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/04/RF_ROT_172628414_low.jpg https://mml.aeb.mwp.accessdomain.com/2017/08/04/fda-reauthorization-bill-enacted-changes-biosimilar-user-fees-review-model/ 2017-08-04T13:59:22+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/01/Rx-pharmacy.jpg https://mml.aeb.mwp.accessdomain.com/2017/08/09/samsung-bioepis-merck-launch-renflexis-u-s/ 2017-08-09T16:15:08+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/01/Rx-pharmacy.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/08/Biosimilars-Approved-by-FDA-BiosimilarsIP.png https://mml.aeb.mwp.accessdomain.com/2017/08/10/sandoz-enters-ipr-battlefield-humira-patents/ 2017-08-10T13:36:25+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Patent-Illustration.jpg https://mml.aeb.mwp.accessdomain.com/2017/08/11/two-new-applications-trastuzumab-herceptin-biosimilars-pending-fda/ 2017-08-11T14:43:39+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Network-connection.jpg https://mml.aeb.mwp.accessdomain.com/2017/08/15/abbvie-files-bpcia-suit-boehringer-ingelheim-humira-adalimumab/ 2017-08-15T22:05:21+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Antibody.jpg https://mml.aeb.mwp.accessdomain.com/2017/08/17/impact-biosimilars-global-pharmaceutical-markets/ 2017-08-17T13:06:43+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/04/RF_ROT_172628414_low.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/08/The-Impact-of-Biosimilars-on-Global-Pharmaceutical-Markets.png https://mml.aeb.mwp.accessdomain.com/2017/09/07/u-s-compares-europe-biosimilar-approvals-products-pipeline/ 2017-09-07T21:14:01+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/World-Map.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/06/Biosimilar-Product-Authorization_September-2017-1.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/06/European-Medicines-Agency-List-of-Approved-Biosimilars_September-2017-1.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/06/US-FDA-List-of-Approved-Biosimilars_September-2017.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/06/EMA-Biosimilars-Uder-Evaluation_September-2017.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/06/Biologics-with-recent-or-nearing-patent-expiry_September-2017.png https://mml.aeb.mwp.accessdomain.com/2017/10/04/pfizer-files-another-ipr-genentechs-%ca%bc441-patent/ 2017-10-04T22:55:14+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Scales-of-Justice.jpg https://mml.aeb.mwp.accessdomain.com/2017/10/05/abbvie-amgen-settle-humira-patent-litigation/ 2017-10-05T18:07:09+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Gavel.jpg https://mml.aeb.mwp.accessdomain.com/2017/10/12/pfizer-seeks-inter-partes-review-rituximab-patents/ 2017-10-12T21:12:16+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Flask-Perodic-Table-Structures.jpg https://mml.aeb.mwp.accessdomain.com/2017/10/17/genentechs-carter-%ca%bc213-patent-continues-draw-ipr-challenges/ 2017-10-17T14:52:34+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/10/Genentech-Carter-213.png https://mml.aeb.mwp.accessdomain.com/2017/10/19/sanofi-files-suit-merck-sharp-dohme-second-nda-insulin-glargine-biologic-look-differences-biosimilar-approval-pathways/ 2017-10-19T16:46:19+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Patent-Illustration.jpg https://mml.aeb.mwp.accessdomain.com/2017/10/23/ptab-denies-institution-rituxan-iprs-petitioner-failed-establish-certain-references-publicly-available/ 2017-10-23T23:22:42+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/United-States-Seal.jpg https://mml.aeb.mwp.accessdomain.com/2017/10/26/ptab-institutes-review-four-celltrion-petitions-targeting-herceptin/ 2017-10-26T14:54:52+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Network-connection.jpg https://mml.aeb.mwp.accessdomain.com/2017/10/30/sanodozs-application-neulasta-pegfilgrastim-accepted-review-europe/ 2017-10-30T20:19:38+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/World-Map.jpg https://mml.aeb.mwp.accessdomain.com/2017/11/07/new-report-says-biosimilars-save-54-billion-biologics-spending/ 2017-11-07T14:41:51+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/04/RF_ROT_172628414_low.jpg https://mml.aeb.mwp.accessdomain.com/2017/11/13/humiras-wall-patents-continues-come-attack/ 2017-11-13T18:53:16+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/glass-vials.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/11/Table-1.-IPRs-Filed-By-Sandoz-Inc.-Against-Humira-Patents.png https://mml.aeb.mwp.accessdomain.com/2017/11/20/federal-circuit-affirms-apotex-filgrastim-neupogen-pegfilgrastim-neulasta-litigation-2/ 2017-11-20T16:17:26+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Scales-of-Justice.jpg https://mml.aeb.mwp.accessdomain.com/2017/11/20/federal-circuit-affirms-apotex-filgrastim-neupogen-pegfilgrastim-neulasta-litigation/ 2017-11-20T16:20:23+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Scales-of-Justice.jpg https://mml.aeb.mwp.accessdomain.com/2017/11/16/update-u-s-compares-europe-biosimilar-approvals-products-pipeline/ 2017-11-21T19:07:10+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/World-Map.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/11/Biosimilar-Product-Authorization-as-of-November-16-2017.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/11/EMA-Approved-Biosimilars-11.16.17-2.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/11/FDA-Approved-Biosimilar-Drugs-as-of-11.16.2017.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/11/EMA-Biosimilars-Under-Evaluation-11.16.2017.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/11/US-Biologics-Near-Primary-Patent-Expiry.png https://mml.aeb.mwp.accessdomain.com/2017/11/28/one-three-pfizer-ipr-petitions-instituted-rituxan-patents/ 2017-11-28T18:55:50+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Gavel.jpg https://mml.aeb.mwp.accessdomain.com/2017/12/05/litigation-vs-licensing-manufacturers-two-recently-approved-biosimilars-take-different-approaches-reference-drug-patents/ 2017-12-05T19:39:08+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Flask-Perodic-Table-Structures.jpg https://mml.aeb.mwp.accessdomain.com/2017/12/27/amgen-files-petition-rehearing-en-banc-praluent-written-description-enablement-issues-2/ 2017-12-27T16:34:43+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Antibody.jpg https://mml.aeb.mwp.accessdomain.com/2018/01/05/standing-questioned-federal-circuit-momenta-pharms-v-bristol-myers-squibb-co/ 2018-01-05T16:28:28+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Patent-Illustration.jpg https://mml.aeb.mwp.accessdomain.com/2018/01/05/standing-questioned-federal-circuit-momenta-pharms-v-bristol-myers-squibb-co-2/ 2018-01-05T16:28:28+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Patent-Illustration.jpg https://mml.aeb.mwp.accessdomain.com/2018/01/15/celltrion-teva-file-declaratory-judgment-action-thirty-eight-herceptin-related-patents/ 2018-01-15T16:34:54+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/01/Rx-pharmacy.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/01/2018.01.15-Celltrion-Teva-Patents-in-Suit.png https://mml.aeb.mwp.accessdomain.com/2018/01/02/federal-biosimilars-act-preempts-state-law/ 2018-01-15T16:51:32+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2018/01/16/celltrion-teva-file-declaratory-judgment-action-thirty-seven-rituxan-related-patents/ 2018-01-16T19:09:26+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Network-connection.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/01/Celltrion-Teva-Patents-in-Suit.png https://mml.aeb.mwp.accessdomain.com/2018/01/18/planned-clinical-trial-aflibercept-signals-likely-future-contests-regenerons-eylea/ 2018-01-18T16:05:24+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/glass-vials.jpg https://mml.aeb.mwp.accessdomain.com/2017/12/27/amgen-files-petition-rehearing-en-banc-praluent-written-description-enablement-issues/ 2018-01-22T19:13:07+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Antibody.jpg https://mml.aeb.mwp.accessdomain.com/2018/01/22/amicus-brief-filed-biopharmaceutical-companies-support-amgens-petition-rehearing-en-banc-2/ 2018-01-22T19:28:53+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Gavel.jpg https://mml.aeb.mwp.accessdomain.com/2018/01/22/amicus-brief-filed-biopharmaceutical-companies-support-amgens-petition-rehearing-en-banc/ 2018-01-24T16:53:00+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Gavel.jpg https://mml.aeb.mwp.accessdomain.com/2018/01/24/update-u-s-compares-europe-biosimilar-approvals-products-pipeline-2/ 2018-01-24T20:54:24+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/World-Map.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/01/Biosimilars-Product-Authorizations.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/01/EMA-Approved-Biosimilars-Drugs-January-24-2018.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/01/US-FDA-Approved-Biosimilar-Drugs-December-13-2017-1.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/01/EMA-Biosimilars-Under-Evaluation-January-4-2018-1.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/01/Biologics-Nearing-Patent-Expiry-in-US.png https://mml.aeb.mwp.accessdomain.com/2018/02/05/litigation-spotlight-update-infliximab-remicade-litigation/ 2018-02-05T14:49:03+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/04/RF_ROT_172628414_low.jpg https://mml.aeb.mwp.accessdomain.com/2018/02/07/district-judge-dismisses-amgens-declaratory-judgment-suit-avastin-biosimilar/ 2018-02-07T15:17:00+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Scales-of-Justice.jpg https://mml.aeb.mwp.accessdomain.com/2018/02/14/abbvie-loses-battle-drop-royalties-blockbuster-humira/ 2018-02-14T19:28:58+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Antibody.jpg https://mml.aeb.mwp.accessdomain.com/2018/02/20/lupins-generic-version-tamiflu-joins-band-flu-fighters/ 2018-02-20T14:32:03+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/glass-vials.jpg https://mml.aeb.mwp.accessdomain.com/2018/02/26/sandozs-challenge-two-abbvies-humira-patents-denied-ptab/ 2018-02-26T16:44:19+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2018/03/05/genentechs-carter-213-patent-asserted-challenged/ 2018-03-05T15:56:29+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/01/Rx-pharmacy.jpg https://mml.aeb.mwp.accessdomain.com/2018/03/12/a-rare-successful-challenge-of-a-patent-for-a-method-of-manufacturing-biologic-drugs/ 2018-03-12T17:46:42+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Flask-Perodic-Table-Structures.jpg https://mml.aeb.mwp.accessdomain.com/2018/03/23/immunex-loses-battle-over-institution-of-follow-on-ipr-petitions/ 2018-03-23T14:30:01+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2018/04/03/global-approvals-for-insulin-glargine-promise-a-more-affordable-long-acting-treatment-for-diabetes/ 2018-04-03T18:59:32+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Patent-Illustration.jpg https://mml.aeb.mwp.accessdomain.com/2018/04/13/is-the-tide-turning-for-diagnostic-claims/ 2018-04-13T15:52:15+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Gavel.jpg https://mml.aeb.mwp.accessdomain.com/2018/04/18/ptab-institutes-review-of-an-abbvie-patent-directed-to-treatment-of-psoriatic-arthritis-comprising-administration-of-adalimumab/ 2018-04-18T17:10:29+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Flask-Perodic-Table-Structures.jpg https://mml.aeb.mwp.accessdomain.com/2018/04/19/ptab-institutes-review-of-abbvie-patent-directed-to-treatment-of-chronic-plaque-psoriasis/ 2018-04-19T17:41:32+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Antibody.jpg https://mml.aeb.mwp.accessdomain.com/2018/04/20/fujifilm-and-mylan-announce-partnership-to-commercialize-adalimumab-biosimilar/ 2018-04-20T19:34:35+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/04/RF_ROT_172628414_low.jpg https://mml.aeb.mwp.accessdomain.com/2018/04/26/final-judgment-entered-in-amgen-v-coherus-neulasta-litigation-2/ 2018-04-26T14:48:22+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Gavel.jpg https://mml.aeb.mwp.accessdomain.com/2018/04/26/final-judgment-entered-in-amgen-v-coherus-neulasta-litigation/ 2018-04-26T14:52:28+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Gavel.jpg https://mml.aeb.mwp.accessdomain.com/2018/05/07/sandoz-receives-complete-response-letter-from-fda-for-proposed-rituximab-biosimilar/ 2018-05-07T17:47:21+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/01/Rx-pharmacy.jpg https://mml.aeb.mwp.accessdomain.com/2018/05/10/ptab-denies-inter-partes-review-of-rituxan-patents/ 2018-05-10T15:41:08+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Scales-of-Justice.jpg https://mml.aeb.mwp.accessdomain.com/2018/05/02/how-the-u-s-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline/ 2018-05-10T15:47:49+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/World-Map.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/05/Biosimilar-Product-Authorizations_5_2018.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/05/EMA-Approved-Biosimilars_5_2018-1.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/05/FDA-Approved-Biosimilars_5_2018.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/05/EMA-Biosimilars-Under-Evaluation_5_2018.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/05/US-Biomsilars-Expiration_5_2018.png https://mml.aeb.mwp.accessdomain.com/2018/05/11/district-court-grants-genentechs-motions-to-dismiss-celltrions-declaratory-judgment-actions-in-herceptin-and-rituxan-related-suits/ 2018-05-11T18:32:32+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2018/05/15/fda-approves-retacrit-as-a-biosimilar-to-epogen/ 2018-05-16T16:05:27+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/glass-vials.jpg https://mml.aeb.mwp.accessdomain.com/2018/05/17/ptab-denies-sandozs-ipr-petition-for-humira-related-patent/ 2018-05-17T13:52:14+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/United-States-Seal.jpg https://mml.aeb.mwp.accessdomain.com/2018/05/18/celltrion-seeks-joinder-with-pfizer-ipr-challenging-rituximab-related-patent/ 2018-05-18T14:24:05+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Network-connection.jpg https://mml.aeb.mwp.accessdomain.com/2018/05/22/litigation-spotlight-update-epogen-litigation-status-in-face-of-retacrit-regulatory-approval/ 2018-05-22T13:46:26+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/04/RF_ROT_172628414_low.jpg https://mml.aeb.mwp.accessdomain.com/2018/05/23/novartis-and-amgen-announce-fda-approval-of-aimovig/ 2018-05-23T20:47:35+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Flask-Perodic-Table-Structures.jpg https://mml.aeb.mwp.accessdomain.com/2018/05/29/litigation-spotlight-the-adello-filgrastim-neupogen-litigation/ 2018-06-04T14:14:25+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Gavel.jpg https://mml.aeb.mwp.accessdomain.com/2018/05/25/lilly-announces-positive-results-for-galcanezumab-in-treating-episodic-cluster-headaches/ 2018-06-04T14:17:04+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/01/Rx-pharmacy.jpg https://mml.aeb.mwp.accessdomain.com/2018/06/14/ptab-denies-another-ipr-petition-relating-to-adalimumab/ 2018-06-14T14:45:46+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Patent-Illustration.jpg https://mml.aeb.mwp.accessdomain.com/2018/06/29/u-s-fda-approves-first-biosimilar-to-neulasta/ 2018-06-29T15:41:16+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Antibody.jpg https://mml.aeb.mwp.accessdomain.com/2018/07/03/new-proposed-legislation-the-hatch-waxman-integrity-act-of-2018/ 2018-07-03T13:45:46+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2018/07/12/genentech-files-two-new-lawsuits-against-celltrion-alleging-infringement-of-patents-related-to-rituxan-and-herceptin/ 2018-07-12T19:49:57+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/glass-vials.jpg https://mml.aeb.mwp.accessdomain.com/2018/07/16/genentech-files-suit-alleging-eli-lillys-taltz-product-infringes-a-newly-issued-genentech-patent/ 2018-07-16T19:01:31+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/United-States-Seal.jpg https://mml.aeb.mwp.accessdomain.com/2018/07/24/first-ipr-against-biogens-172-patent-instituted-after-multiple-attempts/ 2018-07-24T15:09:14+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Scales-of-Justice.jpg https://mml.aeb.mwp.accessdomain.com/2018/08/01/ptab-institutes-a-second-ipr-on-rituxan-related-821-patent/ 2018-08-01T15:24:49+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Flask-Perodic-Table-Structures.jpg https://mml.aeb.mwp.accessdomain.com/2018/08/02/how-the-u-s-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline-2/ 2018-08-02T14:54:20+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/World-Map.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/08/Biosimilar-Product-Authorization_AUgust_2018.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/08/EMA-List-of-Approved-Biosimilars_August_2018.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/08/FDA_List_of_Approved_Biosimilars_August_2018.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/08/EMA_Biosimilars_Under_Evaluation_August_2018.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/08/US_Biologics_Expired_Nearing_Expiry_August_2018.png https://mml.aeb.mwp.accessdomain.com/2018/08/14/abbvie-files-suit-against-sandoz-alleging-infringement-of-two-humira-related-patents/ 2018-08-14T15:31:41+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/01/Rx-pharmacy.jpg https://mml.aeb.mwp.accessdomain.com/2018/08/20/celltrions-and-hospiras-production-of-infliximab-biosimilars-does-not-infringe-remicide-related-patent/ 2018-08-20T19:39:28+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Patent-Illustration.jpg https://mml.aeb.mwp.accessdomain.com/2018/08/30/third-times-a-charm-amgen-files-another-bpcia-lawsuit-against-apotex/ 2018-08-30T13:34:28+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Antibody.jpg https://mml.aeb.mwp.accessdomain.com/2018/09/11/pfizer-loses-out-on-its-follow-on-petition-challenges-to-genentechs-anti-her2-patents-because-it-did-not-follow-general-plastics-guidance/ 2018-09-11T15:55:13+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2018/10/29/how-the-u-s-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline-3/ 2018-10-29T15:21:25+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/World-Map.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/10/EMA_Biosimilars_Authorization_October_2018-2.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/10/FDA_Approved_Biosimilars_October_2018.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/10/EMA_Biosimilars_Under_Evaluation_October_2018.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2018/10/US_Biologics_Expired_Nearing_Expiry_October_2018.png https://mml.aeb.mwp.accessdomain.com/2018/11/05/ptab-exercises-its-%c2%a7-325d-discretion-to-deny-ipr-of-piglet-vaccine-patent/ 2018-11-05T14:54:07+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/glass-vials.jpg https://mml.aeb.mwp.accessdomain.com/2018/11/14/rfems-biosimilar-inter-partes-review-ipr-dashboard-2-2/ 2018-11-14T11:00:34+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2016/08/RF-Generic-Logo-sm.jpg https://mml.aeb.mwp.accessdomain.com/2018/11/15/usmca-assailed-as-exacerbating-high-drug-prices/ 2018-11-15T21:41:05+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2018/12/03/ptab-final-written-decision-finds-all-claims-1-5-of-u-s-patent-no-8821873-obvious-over-the-combination-of-five-prior-art-references/ 2018-12-03T18:15:46+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Scales-of-Justice.jpg https://mml.aeb.mwp.accessdomain.com/2018/12/11/claims-of-genentechs-carter-213-patent-found-unpatentable/ 2018-12-11T20:23:24+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Patent-Illustration.jpg https://mml.aeb.mwp.accessdomain.com/2018/12/21/the-continuing-evolution-of-obviousness-type-double-patenting/ 2018-12-21T15:06:18+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Flask-Perodic-Table-Structures.jpg https://mml.aeb.mwp.accessdomain.com/2019/01/07/fda-proposes-to-amend-the-definition-of-biological-product/ 2019-01-07T18:42:23+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Network-connection.jpg https://mml.aeb.mwp.accessdomain.com/2019/01/11/fda-issues-new-guidance-on-biosimilar-development-under-the-bpcia/ 2019-01-11T17:00:50+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/04/RF_ROT_172628414_low.jpg https://mml.aeb.mwp.accessdomain.com/2019/01/16/fda-issues-guidance-documents-on-the-deemed-to-be-a-license-transition-provision-of-the-bpcia/ 2019-01-16T19:40:59+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2019/01/31/the-ptab-denies-institution-of-two-iprs-involving-a-patent-directed-to-the-treatment-of-hemophilia-b/ 2019-01-31T15:41:43+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/glass-vials.jpg https://mml.aeb.mwp.accessdomain.com/2019/02/05/fdas-biosimilar-approvals-accelerate-in-2018-how-the-u-s-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline/ 2019-02-05T20:38:19+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/World-Map.jpg http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2019/02/Biosimilar-Product-Authorization-2.5.2019.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2019/02/Table-1-2.5.2019.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2019/02/Table-2-2.5.2019.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2019/02/Table-3-2.5.2019.png http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2019/02/Table-4-2.5.2019.png https://mml.aeb.mwp.accessdomain.com/2019/02/22/sandoz-files-declaratory-judgment-of-non-infringement-for-filgrastim-related-patent/ 2019-02-22T19:56:43+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Courthouse-steps-1.jpg https://mml.aeb.mwp.accessdomain.com/2019/02/27/the-third-time-is-the-charm-for-sanofi-in-its-ipr-challenge-of-immunexs-%ca%bc487-patent/ 2019-02-27T21:12:05+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/01/Rx-pharmacy.jpg https://mml.aeb.mwp.accessdomain.com/2019/03/15/biosimilars-will-get-special-names-suffixes-are-here-to-stay/ 2019-03-15T14:31:08+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/03/Antibody.jpg https://mml.aeb.mwp.accessdomain.com/2019/03/18/jury-finds-amgen-antibody-patents-not-invalid/ 2019-03-18T19:54:45+00:00 http://mml.aeb.mwp.accessdomain.com/wp-content/uploads/2017/02/Patent-Illustration.jpg